IL10 and metabolic dysfunction-associated steatotic liver disease: It has been suggested that IL‐10 expression levels are decreased in nonalcoholic steatohepatitis (NASH) and the worsening of pro‐inflammatory markers and insulin resistance when neutralizing anti‐IL‐10 antibodies have been used in a diet‐induced mouse model of NAFLD [34].